F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim

New Investment from Forbion and Sofinnova Partners MANCHESTER, England, Aug. 4, 2022 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development

Related Keywords

Germany ,Milan ,Lombardia ,Italy ,Paris ,France General ,France ,Netherlands ,United Kingdom ,Morningside ,North Lanarkshire ,Singapore ,Austria ,Manchester ,London ,City Of ,Dutch ,Kostenloser Wertpapierhandel ,Joe Anderson ,Francesco Maria Lavino ,Forbion Growth Opportunities Fund ,Shionogi Co Ltd ,Advent Life Sciences ,European Recovery Programme ,Drug Administration ,Cg Ltd ,European Medicines Agency ,Dutch Venture Initiative ,Novo Holdings ,New Investment ,Sofinnova Partners ,Morningside Ventures ,Cowen Healthcare Investments ,Advent Life ,Breakthrough Therapy Designation ,Maria Lavino ,Chief Executive Officer ,General Partner ,Qualified Infectious Disease Product ,United Nations Principles ,Kfw Capital ,Capital Fonds ,Announces ,Billion ,Financing ,Advance ,Development ,Ommercialization ,Antifungal ,Agent ,Lorofim ,